Jianfeng Group Lin2015 -029 (Maternal and Child Health Hospital)
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Jianfeng Group Announcement No.: 2015-029
Bond Abbreviation: 13 Peak 01 Bond Code: 122227
Bond Abbreviation: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Prompt Announcement on Proposed Participation in Relocation of Jinhua Maternal and Child Health Hospital
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Reminder:
l Name of Investment Target: Relocation of Jinhua Maternal and Child Health Hospital
l Special Risk Reminder: The project is still under preliminary planning and planning and must be approved by relevant government departments. There is also uncertainty.
Overview of 1. Foreign Investment
Basic Information of (I) Foreign Investment: Jinhua Maternal and Child Health Hospital is a non-profit maternal and child health care institution that undertakes the public and management functions of maternal and child health care in Jinhua City. At present, the hospital has approved 150 beds and is a second-class maternal and child health care hospital integrating prevention, health care, medical treatment and scientific research, the hospital has obstetrics and gynecology, gynecology, breast, internal medicine, pediatrics and other medical and technical departments. According to the development strategy of "healthy Jinhua" and the requirements of building the fourth medical center in Zhejiang Province, the Jinhua municipal government, in order to enhance the comprehensive service capacity of maternal and child health care in Jinhua and improve the level of maternal and child public health services, put forward the idea of overall relocation of Jinhua maternal and child health care hospital, which requires the construction according to the standard of Grade 3A maternal and child health care hospital, And strive to become "Zhejiang central maternal and child health care center".
According to the Notice of the General Office of the State Council on Further Encouraging and Guiding Social Capital to Hold Medical Institutions and other relevant policies. According to the company's strategic policy, combined with the needs of the development of the company's pharmaceutical and health business sectors, the company plans to apply to the Health and Family Planning Commission and other relevant government departments to participate in the relocation of Jinhua Maternal and Child Health Hospital.
(II) Board of Directors Deliberation: The company held the 5th meeting of the 9th board of directors by correspondence on October 30, 2015. All nine directors of the company participated in the meeting. After deliberation and voting, the board of directors passed the "Proposal on Participating in the Relocation of Jinhua Maternal and Child Health Hospital" with 9 votes in favor and 0 votes against and 0 abstentions.(III) The project is still in the early stage, planning, and need to be reported to the relevant government departments for approval. If the company is allowed to participate in the relocation and construction of Jinhua Maternal and Child Health Hospital, the company will further participate in specific studies such as project site selection and construction, and perform corresponding internal approval procedures in accordance with the company's "Articles of Association.
The impact of the 2. on the company
If the project is approved and successfully implemented, it will further expand the company's development in the field of medicine and medical health, extend the company's pharmaceutical business industry chain, and improve the company's Comprehensive competitiveness.
3.-related risks
The project is still in the early stage of conception and planning, and needs to be approved by relevant government departments. There is still uncertainty as to whether the project can be implemented in the end. The company will follow up in accordance with the Shanghai Stock Exchange "Stock Listing Rules" and other relevant provisions of the timely disclosure of progress. Investors are advised to pay attention to investment risks.
hereby announces
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
October 30, 2015
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page